Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | SERPINC1 | P01008 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21067663 | 0.79 | F10 (0.42) | AMDHD2F10CA1CA2CA9 | |
| SCHEMBL20987120 | 0.79 | F10 (0.42) | AMDHD2F10CA1CA2CA9 | |
| SCHEMBL1009127 | 0.79 | F10 (0.42) | AMDHD2F10CA1CA2CA9 | |
| SCHEMBL7209918 | 0.79 | F10 (0.42) | AMDHD2F10CA1CA2CA9 | |
| SCHEMBL16728926 | 0.79 | F10 (0.42) | AMDHD2F10CA1CA2CA9 | |
| SCHEMBL13286928 | 0.79 | F10 (0.42) | AMDHD2F10CA1CA2CA9 | |
| SCHEMBL7209912 | 0.79 | F10 (0.42) | AMDHD2F10CA1CA2CA9 | |
| Sulfuric Acid SCHEMBL21062202 | 0.76 | CA1 (0.46) | CA1CA2CA9KDM4ELMNA | |
| SCHEMBL22988698 | 0.75 | CA1 (0.47) | CA1CA2CA9KDM4ELMNA | |
| SCHEMBL22658152 | 0.75 | CA1 (0.47) | CA1CA2CA9KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539311-B2 | Short-acting heparin-based anticoagulant compounds and methods | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2026-02-03 | — | — | US | disclosed |
| US-20240066048-A1 | SHORT-ACTING HEPARIN-BASED ANTICOAGULANT COMPOUNDS AND METHODS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-02-29 | — | — | US | disclosed |
| US-11903963-B2 | Short-acting heparin-based anticoagulant compounds and methods | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11903963-B2 | Short-acting heparin-based anticoagulant compounds and methods | HPSE, STS, SULT1A1 | AMDHD2 97/4885F10 425/4885CA1 578/4885 |
| US-20240066048-A1 | SHORT-ACTING HEPARIN-BASED ANTICOAGULANT COMPOUNDS AND METHODS | HPSE, STS, SULT1A1 | AMDHD2 97/4885F10 425/4885CA1 578/4885 |
| US-12539311-B2 | Short-acting heparin-based anticoagulant compounds and methods | STS, TPST2, HPSE | AMDHD2 39/4885F10 100/4885CA1 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.